Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. KNX
10. SPY

Go back to Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016

UBS Reiterates Buy on Alexion Pharma (ALXN) Following 4Q EPS Beat

February 4, 2016 8:39 AM EST

UBS maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $200.00 (from $222.00), following the company's 4Q earnings report. ALXN reported a $0.03 EPS beat, despite a $7m miss in Soliris sales, and a $4m miss in operating income, due to a beat on taxes and higher non-operating income.

Analyst... More

Alexion Pharma (ALXN) Tops Q4 EPS by 3c

February 3, 2016 6:32 AM EST

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $1.13, $0.03 better than the analyst estimate of $1.10. Revenue for the quarter came in at $701 million versus the consensus estimate of $702.69 million.

GUIDANCE:

Alexion Pharma sees FY2016 EPS of $5.00-$5.20, versus the consensus of... More